Hormonal alterations in heart failure: anabolic impairment in chronic heart failure - diagnostic, prognostic and therapeutic issues.

Chronic heart failure represents a leading cause of mortality and health care expenditure in developed countries. In the last 20 years, medical therapy of heart failure has dramatically changed thanks to the introduction of agents able to significantly reduce the neurohormonal hyperactivation that underpins the syndrome, and to the growing opportunities of electrical therapies. Although major advances in terms of improved survival and quality of life have been achieved, the reduction in the burden of heart failure is still the primary goal of cardiovascular societies. In the last decades, other research lines have also grown to complement the neurohormonal paradigm. It is increasingly evident that several hormonal systems are down-regulated or impaired in patients with heart failure, including growth and thyroid hormones, androgens and insulin. These abnormalities could be considered interrelated and linked, in turn, to the neurohormonal and cytokine hyperactivation. Since most of these alterations provide prognostic information, these new lines of evidence support the extension of the classical neurohormonal scheme to a more comprehensive pathophysiological model that includes multiple hormonal and metabolic deficiencies. This chapter examines the evidence in support of this concept. Preliminary experience concerning targeted hormonal supplementation or metabolic modulation is also briefly reviewed in this article.

[1]  R. Granata,et al.  Cardiovascular Issues in Endocrinology , 2014 .

[2]  R. Napoli,et al.  Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. , 2013, JACC. Heart failure.

[3]  R. Kloner,et al.  Testosterone and the Cardiovascular System: A Comprehensive Review of the Basic Science Literature , 2013, Journal of the American Heart Association.

[4]  Daniel B Mark,et al.  Thyroid function in heart failure and impact on mortality. , 2013, JACC. Heart failure.

[5]  C. Lang,et al.  The effect of metformin on insulin resistance and exercise parameters in patients with heart failure , 2012, European journal of heart failure.

[6]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[7]  P. Netti,et al.  Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model , 2012, Diabetes.

[8]  A. Cohen-Solal,et al.  Trends in death attributed to heart failure over the past two decades in Europe , 2012, European journal of heart failure.

[9]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[10]  W. März,et al.  Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography , 2011, European journal of heart failure.

[11]  Takeshi Kimura,et al.  Insulin‐like growth factor axis (insulin‐like growth factor‐I/insulin‐like growth factor‐binding protein‐3) as a prognostic predictor of heart failure: association with adiponectin , 2010, European journal of heart failure.

[12]  P. Ponikowski,et al.  Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure , 2010, European journal of heart failure.

[13]  H. Völzke,et al.  Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. , 2010, European heart journal.

[14]  P. Hildebrandt,et al.  Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[15]  Minoru Horie,et al.  Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure: The Impact of Oxidative Stress , 2009, Circulation. Heart failure.

[16]  F. Iellamo,et al.  Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. , 2009, Journal of the American College of Cardiology.

[17]  L. Saccá,et al.  Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  L. Saccá Heart failure as a multiple hormonal deficiency syndrome. , 2009, Circulation. Heart failure.

[19]  A. L'Abbate,et al.  Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  P. Komesaroff Unravelling the enigma of dehydroepiandrosterone: moving forward step by step. , 2008, Endocrinology.

[21]  A. El-Menyar Cytokines and myocardial dysfunction: state of the art. , 2008, Journal of cardiac failure.

[22]  M. Dowsett,et al.  Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study , 2007, Circulation.

[23]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[24]  D. Bonaduce,et al.  NT-proBNP, IGF-I and survival in patients with chronic heart failure. , 2007, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[25]  A. Araujo,et al.  Sex steroids and all-cause and cause-specific mortality in men. , 2007, Archives of internal medicine.

[26]  Stefan Störk,et al.  Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.

[27]  D. Pennell,et al.  Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  K. Channer,et al.  The effect of testosterone on insulin sensitivity in men with heart failure , 2007, European journal of heart failure.

[29]  P. Ponikowski,et al.  Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival , 2006, Circulation.

[30]  J. Kaufman,et al.  The decline of androgen levels in elderly men and its clinical and therapeutic implications. , 2005, Endocrine reviews.

[31]  P. Ponikowski,et al.  Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. , 2005, Journal of the American College of Cardiology.

[32]  E. Ingelsson,et al.  Insulin resistance and risk of congestive heart failure. , 2005, JAMA.

[33]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[34]  J. Funder RALES, EPHESUS and redox , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  K. Channer,et al.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  R. Jones,et al.  Testosterone treatment for men with chronic heart failure , 2004, Heart.

[37]  Ralph D'Agostino,et al.  Serum Insulin-like Growth Factor I and Risk for Heart Failure in Elderly Individuals without a Previous Myocardial Infarction: The Framingham Heart Study , 2003, Annals of Internal Medicine.

[38]  R. Napoli,et al.  Acute effects of growth hormone on vascular function in human subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[39]  A. L'Abbate,et al.  Low-T3 Syndrome: A Strong Prognostic Predictor of Death in Patients With Heart Disease , 2003, Circulation.

[40]  P. Sönksen,et al.  The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasis , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[41]  R. Napoli,et al.  Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. , 2002, The Journal of clinical endocrinology and metabolism.

[42]  R. Dietz,et al.  Growth Hormone Treatment in Dilated Cardiomyopathy , 2001, Journal of cardiac surgery.

[43]  B. Walker,et al.  Glucocorticoids and insulin resistance: old hormones, new targets. , 1999, Clinical science.

[44]  P. Poole‐Wilson,et al.  Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.

[45]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[46]  P. Douglas,et al.  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.

[47]  A. Cittadini,et al.  Growth hormone and the heart. , 1994, Endocrine reviews.

[48]  B. Trimarco,et al.  Acute noradrenergic activation induces insulin resistance in human skeletal muscle. , 1994, The American journal of physiology.

[49]  B. Bengtsson,et al.  Premature mortality due to cardiovascular disease in hypopituitarism , 1990, The Lancet.

[50]  E. Vittinghoff,et al.  Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. , 2008, Journal of the American College of Cardiology.

[51]  P. Chanson,et al.  Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[52]  J. Mckinlay,et al.  Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. , 2001, American journal of epidemiology.

[53]  C. Edwards,et al.  Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. , 1988, Lancet.